Epidermal growth factor receptor (EGFR) is occasionally amplified and/or mutated in non–
small cell lung cancer (NSCLC) and can be coexpressed with other members of the HER …

EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly
Head | PLOS Medicine Skip to main content Advertisement PLOS Medicine Browse Current …

Background The EGFR T790M mutation confers acquired resistance to kinase inhibitors in
human EGFR mutant lung adenocarcinoma, is occasionally detected before treatment, and …

Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor
pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and …

7020 Background: The EGFR TK inhibitor erlotinib is a standard treatment in previously
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …

Fig 1. Effects of L747S and T790M in the sensitivity of L858R-EGFR to gefitinib and
erlotinib.(A) Ba/F3 cells stably containing constructs with the L858R, L858R-L747S or …

Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …

Specific oncogenes with driver mutations, such as the Epidermal Growth Factor Receptor
(EGFR 1) gene can lead to non-small-cell lung cancer formation. Identification of these …

Purpose Sensitivity to a tyrosine kinase inhibitor (TKI) is correlated with the presence of
somatic mutations that affect the kinase domain of epidermal growth factor receptor (EGFR) …

Despite the success of treating EGFR-mutant lung cancer patients with EGFR tyrosine
kinase inhibitors (TKI), all patients eventually acquire resistance to these therapies. Although …